About Alvine Pharma
Alvine Pharma is a company based in San Carlos (United States) founded in 2005 was acquired by Immunogenx in March 2016. Alvine Pharma has raised $128.51 million across 6 funding rounds from investors including AbbVie, Flagship Pioneering and Immunogenx. Alvine Pharma offers products and services including LLC Formation Service, Registered Agent Service, and Trademark Service. Alvine Pharma operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter San Carlos, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$128.51 M (USD)
in 6 rounds
-
Latest Funding Round
$70 M (USD), Series B
May 14, 2013
-
Investors
AbbVie
& 8 more
-
Employee Count
Not available
-
Acquired by
Immunogenx
(Mar 15, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alvine Pharma
Alvine Pharma offers a comprehensive portfolio of products and services, including LLC Formation Service, Registered Agent Service, and Trademark Service.
Assists in forming limited liability companies for business owners.
Handles legal documents and ensures business compliance requirements.
Provides guidance on protecting business brands and trademarks.
Funding Insights of Alvine Pharma
Alvine Pharma has successfully raised a total of $128.51M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $70 million completed in May 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alvine Pharma
Alvine Pharma has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Flagship Pioneering and Immunogenx.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early & later stage venture capital firm investing in the US
|
Locked | Locked | Locked | |
|
Early-stage investing in IT and healthcare ventures.
|
Locked | Locked | Locked | |
|
Investments are made in US life sciences and healthtech firms.
|
Locked | Locked | Locked |
Investor details for Alvine Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alvine Pharma
Investment portfolio details for Alvine Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alvine Pharma
Detailed financials for Alvine Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alvine Pharma Comparisons
Peer comparison for Alvine Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alvine Pharma
Alvine Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Alvine Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alvine Pharma
Complete news archive for Alvine Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alvine Pharma
Alvine Pharma was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Alvine Pharma is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Alvine Pharma is a funded company, having raised a total of $128.51M across 6 funding rounds to date.
Alvine is developing biologics to target autoimmuneinflammatory diseases. The companys initial focus targets celiac disease. Celiac disease is a gluten-induced autoimmune disease for which no drug therapy is presently available. Alvines lead product candidate, ALV003, is a combination protease engineered to digest gluten and is currently in phase 2b.
Alvine Pharma's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
Alvine Pharma offers LLC Formation Service, Registered Agent Service, and Trademark Service.
Alvine Pharma has 9 investors. Key investors include AbbVie, Flagship Pioneering, Immunogenx, Panorama Capital, and InterWest.